• Acumen flagged new preclinical data on its Enhanced Brain Delivery technology ahead of AAIC 2026 in London on July 12-15.
• Key update centers on bispecific antibodies targeting amyloid beta oligomers and transferrin receptors, showing enhanced brain delivery in cynomolgus monkeys.
• Additional AAIC presentations include transferrin receptor-mediated transport work and patient-perspective findings from the ALTITUDE-AD trial population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070730PRIMZONEFULLFEED9756432) on July 07, 2026, and is solely responsible for the information contained therein.